2-Star Stocks Poised to Plunge: Nymox Pharmaceutical?

Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biopharmaceutical company Nymox Pharmaceutical (Nasdaq: NYMX  ) has received a distressing two-star ranking.

With that in mind, let's take a closer look at Nymox and see what CAPS investors are saying about the stock right now.

Nymox facts

Headquarters (founded)

St Laurent, Canada (1989)

Market Cap

$279.1 million

Industry

Biotechnology

Trailing-12-Month Revenue

$3.1 million

Management

CEO Dr. Paul Averback (since 1995)
CFO Roy Wolvin (since 1995)

Return on Assets (average, past three years)

(202.1%)

Cash/Debt

$2.2 million / $0

Competitors

Abbott Labs (NYSE: ABT  )
Innogenetics
Laboratory Corp.
(NYSE: LH  )

Sources: S&P Capital IQ; Motley Fool CAPS.

On CAPS, 38% of the 82 members who have rated Nymox believe the stock will underperform the S&P 500 going forward.

Just last week, one of those Fools, All-Star zzlangerhans, cautioned our community about the stock's recent surge:

When Nymox stock trailed down from steady state at [$8 per share] to below [$6 per share] this summer, I figured the smart money was leaving ahead of negative results from the phase III trials of NX-1207 for BPH. Now I'm surprised to see the share price rocketing back up close to the year high without any visible positive catalyst. This definitely doesn't have the characteristics of a run-up, so is it insider trading ahead of a positive data announcement? I can't say that's impossible, but I'm going to call it stirrapulation and place my bet on negative data from this murky trial from a very murky biopharma.

We've found another growth play we are incredibly excited about -- excited enough to dub it "The Only Stock You Need to Profit from the NEW Technology Revolution." We have compiled a special free report for investors to uncover this stock today. The report is 100% free, but it won't be here forever, so click here to access it now.

Want to see how well (or not so well) the stocks in this series are performing? Follow the TrackPoisedTo CAPS account.


Read/Post Comments (0) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2107680, ~/Articles/ArticleHandler.aspx, 9/19/2014 12:10:52 PM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Apple's next smart device (warning, it may shock you

Apple recently recruited a secret-development "dream team" to guarantee its newest smart device was kept hidden from the public for as long as possible. But the secret is out. In fact, ABI Research predicts 485 million of this type of device will be sold per year. But one small company makes Apple's gadget possible. And its stock price has nearly unlimited room to run for early-in-the-know investors. To be one of them, and see Apple's newest smart gizmo, just click here!


Advertisement